Prognostic value of HMGB1 in early breast cancer patients under neoadjuvant chemotherapy

The response to neoadjuvant chemotherapy in breast cancer patients is usually assessed by pCR and RCB score. However, the prognostic value of these parameters is still in discussion. We showed recently that an epirubicin/docetaxel therapy is associated with an increase in the cell death marker high‐...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Cancer Med
Glavni autori: Exner, Ruth, Sachet, Monika, Arnold, Tobias, Zinn‐Zinnenburg, Mercedes, Michlmayr, Anna, Dubsky, Peter, Bartsch, Rupert, Steger, Guenther, Gnant, Michael, Bergmann, Michael, Bachleitner‐Hofmann, Thomas, Oehler, Rudolf
Format: Artigo
Jezik:Inglês
Izdano: John Wiley and Sons Inc. 2016
Teme:
Clinical Cancer Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5055166/
https://ncbi.nlm.nih.gov/pubmed/27457217
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.827
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items